AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: Marie McCullough
Nov. 21--Scientists have developed a vaccine against a type of papilloma virus, a big step toward curbing the world's most common sexually transmitted disease and protecting women from its worst consequences -- cervical cancer.
If the vaccine lives up to its early promise, it could mean the eventual eradication of cervical cancer, which annually kills about 4,000 American women and 250,000 women worldwide.
A vaccine approved by the federal Food and Drug Administration could be on the market in about five years, researchers said.
Four types of human papilloma virus are believed to cause virtually all cervical cancer. The experimental inoculation works against only one type -- HPV type 16, linked to half of cervical cancers -- but other HPV types ultimately will be added, said Kathrin U. Jansen, a senior director at Merck Research Laboratories in West Point, Montgomery County, which is funding the vaccine development.
In a study published today in the New England Journal of Medicine, Jansen and her colleagues at four universities report that the vaccine…